Thermo Fisher Scientific Gestione

Gestione criteri di controllo 3/4

Thermo Fisher Scientific Il CEO è Marc Casper, nominato in Oct2009, e ha un mandato di 15.08 anni. la retribuzione annua totale è $ 18.98M, composta da 9.1% di stipendio e 90.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.038% delle azioni della società, per un valore di $ 75.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 12.7 anni.

Informazioni chiave

Marc Casper

Amministratore delegato

US$19.0m

Compenso totale

Percentuale dello stipendio del CEO	9.1%
Mandato del CEO	15.1yrs
Proprietà del CEO	0.04%
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	12.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Marc Casper rispetto agli utili di Thermo Fisher Scientific?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 28 2024	n/a	n/a	US$6b
Jun 29 2024	n/a	n/a	US$6b
Mar 30 2024	n/a	n/a	US$6b
Dec 31 2023	US$19m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jul 01 2023	n/a	n/a	US$6b
Apr 01 2023	n/a	n/a	US$6b
Dec 31 2022	US$28m	US$2m	US$7b
Oct 01 2022	n/a	n/a	US$7b
Jul 02 2022	n/a	n/a	US$7b
Apr 02 2022	n/a	n/a	US$8b
Dec 31 2021	US$21m	US$2m	US$8b
Oct 02 2021	n/a	n/a	US$9b
Jul 03 2021	n/a	n/a	US$9b
Apr 03 2021	n/a	n/a	US$8b
Dec 31 2020	US$26m	US$2m	US$6b
Sep 26 2020	n/a	n/a	US$5b
Jun 27 2020	n/a	n/a	US$4b
Mar 28 2020	n/a	n/a	US$4b
Dec 31 2019	US$19m	US$2m	US$4b
Sep 28 2019	n/a	n/a	US$4b
Jun 29 2019	n/a	n/a	US$4b
Mar 30 2019	n/a	n/a	US$3b
Dec 31 2018	US$19m	US$1m	US$3b
Sep 29 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$22m	US$1m	US$2b

Compensazione vs Mercato: La retribuzione totale di Marc ($USD 18.98M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 5.69M ).

Compensazione vs guadagni: La retribuzione di Marc è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Marc Casper (56 yo)

15.1yrs

Mandato

US$18,976,669

Compensazione

Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc Casper	Chairman	15.1yrs	US$18.98m	0.038% $ 75.6m
Stephen Williamson	Senior VP & CFO	9.3yrs	US$6.24m	0.010% $ 20.6m
Michel Lagarde	Executive VP & COO	2.8yrs	US$7.25m	0.0044% $ 8.8m
Lisa Britt	Chief Human Resources Officer & Senior VP	7.7yrs	US$2.89m	0.0035% $ 6.9m
Gianluca Pettiti	Executive Vice President	no data	US$5.73m	0.0044% $ 8.6m
Joseph Holmes	VP & Chief Accounting Officer	3.7yrs	Nessun dato	0.00041% $ 809.4k
Ryan Snyder	Senior VP & Chief Information Officer	5.3yrs	Nessun dato	Nessun dato
Karen Nelson	Chief Scientific Officer	3.3yrs	Nessun dato	Nessun dato
Rafael Tejada	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Michael Boxer	Senior VP & General Counsel	6.8yrs	US$3.12m	0.0032% $ 6.3m
Sandy Pound	VP & Chief Communications Officer	4.1yrs	Nessun dato	Nessun dato
Paul Parker	Senior Vice President of Strategy & Corporate Development	4.6yrs	Nessun dato	Nessun dato

5.0yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 0R0H è considerato esperto (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Marc Casper	Chairman	15.1yrs	US$18.98m	0.038% $ 75.6m
Scott Sperling	Independent Lead Director	18yrs	US$403.12k	0.019% $ 37.2m
C. Harris	Independent Director & Member of Scientific Advisory Board	12.7yrs	US$325.72k	0.0022% $ 4.4m
Nelson Chai	Independent Director	13.9yrs	US$365.72k	0.0037% $ 7.3m
Lars Sorensen	Independent Director	8.5yrs	US$345.72k	0.0024% $ 4.8m
Mark Stevenson	Member of Scientific Advisory Board	no data	US$9.40m	Nessun dato
Tyler Jacks	Member of Scientific Advisory Board & Director	15.5yrs	US$345.72k	0.0022% $ 4.3m
Cynthia Wolberger	Member of Scientific Advisory Board	7yrs	Nessun dato	Nessun dato
William Hahn	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Debora Spar	Independent Director	5.2yrs	US$345.72k	0.00040% $ 789.6k
Steven Gygi	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Dion Weisler	Independent Director	7.7yrs	US$353.19k	0.0012% $ 2.3m

12.7yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0R0H è composto da personale esperto e esperto (durata media dell'incarico 12.7 anni).

Thermo Fisher Scientific Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insider recently sold US$2.2m worth of stock

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Recent updates

Thermo Fisher Scientific Inc. (NYSE:TMO) announces an Equity Buyback for $4,000 million worth of its shares.

Third quarter dividend of US$0.39 announced

Thermo Fisher Scientific Inc. Declares Quarterly Cash Dividend, Payable on January 15, 2025

Third quarter 2024 earnings released: EPS: US$4.27 (vs US$4.44 in 3Q 2023)

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2024

Thermo Fisher Scientific Introduces Fully Integrated Multimodal Analytical Scanning Transmission Electron Microscope to Advance Novel Research in Materials Science

Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity

Thermo Fisher Scientific Inc. to Report Q3, 2024 Results on Oct 23, 2024

Upcoming dividend of US$0.39 per share

Now 20% undervalued

FDA Grants Thermo Fisher Scientific Inc.'s SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Inc. Announces Extended 510k Clearance of Freelite Assays for Evaluation of MGUS

Insider recently sold US$2.2m worth of stock

Thermo Fisher Scientific Inc. Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024

Second quarter 2024 earnings released: EPS: US$4.05 (vs US$3.53 in 2Q 2023)

Thermo Fisher Scientific Inc. Raises Earnings Guidance for the Year 2024

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others.

Thermo Fisher Scientific Inc. to Report Q2, 2024 Results on Jul 24, 2024

Thermo Fisher Scientific Inc.(NYSE:TMO) dropped from Russell 1000 Growth-Defensive Index

Thermo Fisher Scientific Introduces the Only Fully Automated Plasmid Purification System to Help Accelerate Discovery and Development of Therapies

Thermo Fisher Scientific Introduces Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators

Upcoming dividend of US$0.39 per share

Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation

First quarter dividend of US$0.39 announced

Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2024

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research to Support Future Advancements Toward Safer Transfusions

First quarter 2024 earnings released: EPS: US$3.48 (vs US$3.34 in 1Q 2023)

Thermo Fisher Scientific Inc. Raises Revenue Guidance for the Full Year 2024

Thermo Fisher Scientific Inc. Introduces Animal Origin-Free Formulation to Support Scaling of Cell Therapy Manufacturing

Thermo Fisher Scientific Inc., Annual General Meeting, May 22, 2024

Thermo Fisher Scientific Introduces Its Newest Line of High Performance, Ultra-Low Temperature (ULT) Freezers

Thermo Fisher Scientific Inc. to Report Q1, 2024 Results on Apr 24, 2024

Thermo Fisher Scientific Announces A New In-Line Metrology Solution to Improve Battery Safety and Performance

Thermo Fisher Scientific Inc. Launches Corevitas Clinical Registry in Generalized Pustular Psoriasis

Upcoming dividend of US$0.39 per share

Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022)

Fourth quarter dividend increased to US$0.39

Thermo Fisher Scientific Inc. Increases Quarterly Cash Dividend, Payable on April 15, 2024

Thermo Fisher Scientific Inc. Launches New Ion Chromatography Instrument to Improve Reliability, Efficiency, and Functional Adaptability for Labs

Thermo Fisher Scientific Expands GMP Laboratory Service Offerings with Biosafety Testing Including Mycoplasma Testing

Now 20% undervalued

Full year 2023 earnings released: EPS: US$15.53 (vs US$17.73 in FY 2022)

Thermo Fisher Scientific Inc. Announces Earnings Guidance for Full Year 2024

Thermo Fisher Scientific Appoints Srinath Venkatesh as Managing Director, India and South Asia

Thermo Fisher Scientific Receives GMP Approval from the Italian Medicines Agency for its Manufacturing Facility of RNA-Based Products in Monza, Italy

Thermo Fisher Scientific Inc. Announces Launch of Innovative Corevitas Pharmacovigilance Platform for Clinical Research Registries

Thermo Fisher Scientific Inc. Announces the Launch of the Thermo Scientific KingFisher Apex Dx and Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Declares Quarterly Dividend, Payable on January 16, 202

Thermo Fisher Scientific Announces New Fault Localization Solution for the Analysis of Advanced Logic Semiconductors

Thermo Fisher Scientific Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$4.44 (vs US$3.81 in 3Q 2022)

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. (NYSE:TMO) proposed an offer to acquire Olink Holding AB (publ) (NasdaqGM:OLK) from Summa Equity AB and others for approximately $3.3 billion.

Thermo Fisher Scientific Inc. to Report Q3, 2023 Results on Oct 25, 2023

Thermo Fisher Scientific Inc. Appoints Jennifer “Jenny” Johnson to the Audit Committee

Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with A Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™

Upcoming dividend of US$0.35 per share at 0.3% yield

Thermo Fisher Scientific Announces the Launch of the EXENT Solution with IVDR Certification

Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity

Thermo Fisher Scientific Inc. (NYSE:TMO) acquired CorEvitas, LLC from Audax Management Company, LLC for approximately $910 million.

Thermo Fisher Scientific Announces a New Line of Thermo Scientific TM TSG Series Refrigerators

Thermo Fisher Scientific Inc. Revises earnings Guidance for 2023

Second quarter 2023 earnings released: EPS: US$3.53 (vs US$4.25 in 2Q 2022)

Thermo Fisher Scientific Introduces New Reproductive Health Assays to Accelerate Fertility Research

Thermo Fisher Scientific Inc. Elects Jenny Johnson to Board of Directors

Thermo Fisher Scientific Inc. (NYSE:TMO) has entered into a definitive agreement to acquire CorEvitas, LLC from Audax Management Company, LLC for Approximately $910 million.